John Butler, Akebia CEO
February 23, 2022 01:27 PM ESTUpdated February 25, 12:42 PM
Financing
Pharma

Ake­bia scrapes to­geth­er $85M war chest to com­mer­cial­ize va­da as PDU­FA date looms

John Carroll

Editor & Founder

With its PDU­FA date loom­ing at the end of March, Ake­bia has re­vised its com­mer­cial­iza­tion deal with Vi­for, in­ject­ing a quick $85 mil­lion in­to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

A service from the Financial Times